Logo image of SABS

SAB BIOTHERAPEUTICS INC (SABS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SABS - US78397T2024 - Common Stock

3.78 USD
-0.06 (-1.56%)
Last: 12/26/2025, 8:15:05 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SABS. SABS was compared to 530 industry peers in the Biotechnology industry. While SABS seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, SABS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SABS has reported negative net income.
In the past year SABS has reported a negative cash flow from operations.
In the past 5 years SABS reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: SABS reported negative operating cash flow in multiple years.
SABS Yearly Net Income VS EBIT VS OCF VS FCFSABS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

The Return On Assets of SABS (-11.65%) is better than 83.02% of its industry peers.
SABS has a Return On Equity of -12.94%. This is amongst the best in the industry. SABS outperforms 86.79% of its industry peers.
Industry RankSector Rank
ROA -11.65%
ROE -12.94%
ROIC N/A
ROA(3y)-54.75%
ROA(5y)-29.96%
ROE(3y)-88.44%
ROE(5y)-51.64%
ROIC(3y)N/A
ROIC(5y)N/A
SABS Yearly ROA, ROE, ROICSABS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SABS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SABS Yearly Profit, Operating, Gross MarginsSABS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

5

2. Health

2.1 Basic Checks

SABS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for SABS has been increased compared to 1 year ago.
SABS has a worse debt/assets ratio than last year.
SABS Yearly Shares OutstandingSABS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2M 4M 6M 8M
SABS Yearly Total Debt VS Total AssetsSABS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

An Altman-Z score of 5.06 indicates that SABS is not in any danger for bankruptcy at the moment.
SABS's Altman-Z score of 5.06 is fine compared to the rest of the industry. SABS outperforms 72.83% of its industry peers.
SABS has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.02, SABS is in line with its industry, outperforming 43.21% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 5.06
ROIC/WACCN/A
WACC8.74%
SABS Yearly LT Debt VS Equity VS FCFSABS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

A Current Ratio of 10.50 indicates that SABS has no problem at all paying its short term obligations.
The Current ratio of SABS (10.50) is better than 83.21% of its industry peers.
A Quick Ratio of 10.50 indicates that SABS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.50, SABS belongs to the top of the industry, outperforming 83.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.5
Quick Ratio 10.5
SABS Yearly Current Assets VS Current LiabilitesSABS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.62% over the past year.
SABS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -92.42%.
Measured over the past years, SABS shows a very negative growth in Revenue. The Revenue has been decreasing by -72.10% on average per year.
EPS 1Y (TTM)48.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.61%
Revenue 1Y (TTM)-92.42%
Revenue growth 3Y-72.1%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SABS will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.98% on average per year.
SABS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 130.25% yearly.
EPS Next Y45.12%
EPS Next 2Y35.71%
EPS Next 3Y23.52%
EPS Next 5Y13.98%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-19.93%
Revenue Next 5Y130.25%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SABS Yearly Revenue VS EstimatesSABS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
SABS Yearly EPS VS EstimatesSABS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SABS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SABS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SABS Price Earnings VS Forward Price EarningsSABS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SABS Per share dataSABS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as SABS's earnings are expected to grow with 23.52% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.71%
EPS Next 3Y23.52%

More info and screens

0

5. Dividend

5.1 Amount

SABS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SAB BIOTHERAPEUTICS INC

NASDAQ:SABS (12/26/2025, 8:15:05 PM)

3.78

-0.06 (-1.56%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-14 2025-11-14/bmo
Earnings (Next)03-30 2026-03-30/amc
Inst Owners59.15%
Inst Owner Change1356.71%
Ins Owners1.87%
Ins Owner Change13.15%
Market Cap179.97M
Revenue(TTM)114.70K
Net Income(TTM)-21.37M
Analysts85
Price Target9.01 (138.36%)
Short Float %1.68%
Short Ratio2.52
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.34%
Min EPS beat(2)-34.25%
Max EPS beat(2)70.94%
EPS beat(4)2
Avg EPS beat(4)20.03%
Min EPS beat(4)-34.25%
Max EPS beat(4)70.94%
EPS beat(8)4
Avg EPS beat(8)-35.61%
EPS beat(12)7
Avg EPS beat(12)-25.29%
EPS beat(16)10
Avg EPS beat(16)-40.08%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-76.57%
Min Revenue beat(4)-100%
Max Revenue beat(4)-6.29%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-3.99%
EPS NQ rev (1m)42.33%
EPS NQ rev (3m)68.92%
EPS NY rev (1m)11.26%
EPS NY rev (3m)11.26%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1569.01
P/FCF N/A
P/OCF N/A
P/B 1.09
P/tB 1.09
EV/EBITDA N/A
EPS(TTM)-3.03
EYN/A
EPS(NY)-0.59
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.79
OCFYN/A
SpS0
BVpS3.47
TBVpS3.47
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.65%
ROE -12.94%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-54.75%
ROA(5y)-29.96%
ROE(3y)-88.44%
ROE(5y)-51.64%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.5
Quick Ratio 10.5
Altman-Z 5.06
F-Score3
WACC8.74%
ROIC/WACCN/A
Cap/Depr(3y)26.93%
Cap/Depr(5y)828.01%
Cap/Sales(3y)14.46%
Cap/Sales(5y)16.88%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.61%
EPS Next Y45.12%
EPS Next 2Y35.71%
EPS Next 3Y23.52%
EPS Next 5Y13.98%
Revenue 1Y (TTM)-92.42%
Revenue growth 3Y-72.1%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-19.93%
Revenue Next 5Y130.25%
EBIT growth 1Y16.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-178.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-183.73%
OCF growth 3YN/A
OCF growth 5YN/A

SAB BIOTHERAPEUTICS INC / SABS FAQ

Can you provide the ChartMill fundamental rating for SAB BIOTHERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SABS.


Can you provide the valuation status for SAB BIOTHERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to SAB BIOTHERAPEUTICS INC (SABS). This can be considered as Overvalued.


How profitable is SAB BIOTHERAPEUTICS INC (SABS) stock?

SAB BIOTHERAPEUTICS INC (SABS) has a profitability rating of 2 / 10.


How financially healthy is SAB BIOTHERAPEUTICS INC?

The financial health rating of SAB BIOTHERAPEUTICS INC (SABS) is 5 / 10.